18
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      GABAA receptor pharmacology

      Pharmacology & Therapeutics
      Elsevier BV

      Read this article at

      ScienceOpenPublisher
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Most cited references2

          • Record: found
          • Abstract: found
          • Article: not found

          Antibodies specific for alpha-subunit subtypes of GABAA receptors reveal brain regional heterogeneity.

          Antisera were produced in rabbits against synthetic peptides based on subtype-specific regions of the cDNA sequences of the alpha 1, alpha 2, alpha 3, and alpha 4 (also termed alpha 5) subunits of mammalian GABAA receptors. The antigen peptides were chosen from the putative cytoplasmic loop between the proposed third and fourth membrane spanning helices; they were not only subtype-specific sequences, but also their hydrophilicity and predicted secondary structures suggested high potential antigenicity. In all cases, antipeptide antisera recognized on western blots the corresponding alpha-subunit polypeptide of the GABAA receptors purified from bovine brain by benzodiazepine-affinity chromatography, and were able to immunoprecipitate binding activity from detergent-solubilized purified receptors. The four antisera each recognized a unique polypeptide, and only one, in the purified receptor, with alpha 1, alpha 2, alpha 3, and alpha 4 identified at 51, 52, 56, and 57 kDa, respectively. This represents the first identification of the alpha 4 gene product on a gel. Both the relative amount of staining in immunoblots and the fraction of receptor binding that could be immunoprecipitated by saturating concentrations of each of the four subtype-specific antibodies varied in a consistent manner between receptors purified from different brain regions. Thus, cerebral cortex receptor contained all four alpha polypeptides on western blots, and significant activity could be precipitated by all four. Hippocampal receptor lacked alpha 3 immunoreactivity on blotting and by immunoprecipitation; alpha 1 was less, whereas both alpha 2 and alpha 4 were more abundant in hippocampus than in cortex by both techniques. Cerebellum receptor contained only alpha 1 of the four alpha subunits tested, and the anti-alpha 1 antibodies immunoprecipitated > 90% of the binding activity. The variable amounts of staining and immunoprecipitation from the three brain areas by the four antisera demonstrate the presence of heterooligomeric receptor complexes with different alpha-subunit constituents in cortex, hippocampus, and cerebellum. The sum of cortical receptor activity precipitated individually by the four anti-alpha antisera was > 150%, indicating that some heterooligomers are likely to contain more than one class of alpha subtype, although most receptor complexes probably contain only one alpha subtype. These alpha-subunit subtype-specific antibodies should be useful in analyzing structure, function, and localization of GABAA/benzodiazepine receptors in mammalian brain.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Antagonism of inhibitory amino acids by the steroid derivative RU5135.

            The steroid derivative RU5135 has been tested for its ability to antagonize glycine and the gamma-aminobutyric acid (GABA) analogue muscimol on isolated preparations of rat optic nerve and cuneate nucleus, respectively. On the cuneate nucleus, RU5135 antagonized muscimol in a competitive manner with a pA2 value of 8.31. RU5135 shared a common site of action with bicuculline that was separate from the picrotoxin site. On the optic nerve, RU5135 antagonized glycine with a pA2 of 7.67. It shared a common site of action with strychnine.
              Bookmark

              Author and article information

              Journal
              Pharmacology & Therapeutics
              Pharmacology & Therapeutics
              Elsevier BV
              01637258
              January 1996
              January 1996
              : 69
              : 3
              : 173-198
              Article
              10.1016/0163-7258(95)02043-8
              a719d9e9-612a-4412-aef8-77d6d2da685e
              © 1996

              http://www.elsevier.com/tdm/userlicense/1.0/

              History

              Comments

              Comment on this article